Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
Summary
The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug. The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson’s patients. These are times when the standard of care drug, levodopa, wears off and tremors, stiffness, and other symptoms return. The Marlborough, MA-based company resubmitted the file last November with more details about the product’s packaging and additional analyses of clinical data. Last month, Supernus Pharmaceuticals (NASDAQ: SUPN) announced it was acquiring the entire US WorldMeds central nervous system drug portfolio to add Parkinson’s disease products to its lineup.
Classifications
AskAI Classifications
LabelsLinked Companies
